Skip to main content

Advertisement

SpringerLink
Log in

Pneumococcal pneumonia

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Pneumococcal pneumonia accounts for about one-sixth to two-thirds of all cases of community-acquired pneumonia. Its high frequency of occurrence worldwide and the high number of deaths associated with it—especially with bacteremic (invasive) disease—mark its importance. Invasive disease is associated with case-fatality rates of 15% to 25% among elderly adults. Penicillin-resistant Streptococcus pneumoniae (PRSP) first appeared in the 1970s, and its increased incidence in the late 1980s signaled its emerging importance. In individual patients in whom PRSP infection is suspected, the clinician must follow guidelines for empiric antibiotic therapy for community-acquired pneumonia until microbiological test results are known. When a diagnosis of pneumococcal pneumonia is established, the clinician should change to a regimen that targets the pneumococcus. Adults at highest risk for death from pneumococcal pneumonia include immunocompetent persons with underlying chronic diseases, immunocompromised persons, elderly persons, and unvaccinated residents of nursing homes and other chronic care facilities. Safe and effective, polyvalent polysaccharide pneumococcal vaccine should be used in persons 2 years of age and older who are at increased risk for serious pneumococcal pneumonia and in all persons 65 years of age and older.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997, 46:1–24.

  2. Smit P, Oberholzer D, Hayden-Smith S, et al.: Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977, 238:2613–2616.

    Article  PubMed  CAS  Google Scholar 

  3. Austrian R: Prevention of pneumococcal infection by immunization with capsular polysaccharides of Streptococcus pneumoniae: current status of polyvalent vaccines. J Infect Dis 1977, 136(suppl):S38-S42.

    PubMed  Google Scholar 

  4. Shapiro ED, Berg AT, Austrian R, et al.: The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991, 325:1453–1460.

    Article  PubMed  CAS  Google Scholar 

  5. Butler JC, Breiman RF, Campbell JF, et al.: Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993, 270:1826–1831.

    Article  PubMed  CAS  Google Scholar 

  6. Farr BM, Johnston BL, Cobb DK, et al.: Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med 1995, 155:2336–2340.

    Article  PubMed  CAS  Google Scholar 

  7. Koivula I, Sten M, Leinonen M, et al.: Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997, 103:281–290. A randomized trial of 14-valent polysaccharide pneumococcal vaccine conducted in the early 1980s in a single town in Finland. Vaccine protective efficacy was 59% in elderly persons with risk factors for pneumococcal pneumonia. However, in elderly persons without risk factors and in immunocompromised elderly persons, the vaccine showed no efficacy. These findings provide additional evidence of pneumococcal vaccine efficacy in elderly persons at intermediate risk for pneumococcal pneumonia.

    Article  PubMed  CAS  Google Scholar 

  8. Örtqvist A, Hedlund J, Burman LA, et al.: Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998, 351:399–403. A double-blind, randomized, placebo-controlled trial of 23-valent polysaccharide pneumococcal vaccine conducted in the early 1990s in Sweden among adults 50 years of age and older who had previously had pneumonia. In this study, the vaccine did not prevent pneumococcal pneumonia. Bacteremia was detected in only six persons (one in the vaccine group and five in the placebo group), suggesting a vaccine protective effect (point estimate of vaccine efficacy, 79%; P= 0.23).

    Article  PubMed  Google Scholar 

  9. Fedson DS, Shapiro ED, LaForce FM, et al.: Pneumococcal vaccine after 15 years of use. Another view. Arch Intern Med 1994, 154:2531–2535.

    Article  PubMed  CAS  Google Scholar 

  10. Mufson MA. Editorial response: penicillin-resistant Streptococcus pneumoniae increasingly threatens the patient and challenges the physician. Clin Infect Dis 1998, 27:771–773.

    PubMed  CAS  Google Scholar 

  11. Zighelboim S, Tomasz A: Multiple antibiotic resistance in South African strains of Streptococcus pneumoniae: mechanism of resistance to beta-lactam antibiotics. Rev Infect Dis 1981, 3:267–276.

    PubMed  CAS  Google Scholar 

  12. Doern GV, Pfaller MA, Kugler K, et al.: Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1998, 27:764–770. This multicenter study reports on the increasing development of penicillin resistance among a large number of pneumococcal isolates from the respiratory tract. The authors found that 43.8% of isolates were PRSP (16.0% were highly resistant PRSP), representing the highest rates of occurrence thus far in the United States.

    PubMed  CAS  Google Scholar 

  13. Watanakunakorn C, Bailey TA:Adult bacteremic pneumococcal pneumonia in a community teaching hospital, 1992–1996. A detailed analysis of 108 cases. Arch Intern Med 1997, 157:1965–1971. The authors analyze all cases of bacteremic pneumococcal pneumonia in patients admitted between 1992 and 1996 to a community teaching hospital in Youngstown, Ohio. Their findings affirm that invasive disease is more severe in elderly adults, that the highest casefatality rates occur in persons 85 years of age and older, and that risk factors are associated with increased case-fatality rates.

    Article  PubMed  CAS  Google Scholar 

  14. Marrie TJ. Community-acquired pneumonia: epidemiology, etiology, treatment. Infect Dis Clin North Am 1998, 12:723–740.

    Article  PubMed  CAS  Google Scholar 

  15. Bartlett JG, Breiman RF, Mandell LA, et al.: Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis 1998, 26:811–838. sensus report of the Infectious Diseases Society of America on the empiric treatment of community-acquired pneumonia, including pneumococcal pneumonia. These recommendations provide expert advice for selecting appropriate antibiotics before the results of microbiological cultures are available

    PubMed  CAS  Google Scholar 

  16. Woodhead M: Community-acquired pneumonia guidelines-an international comparison: a view from Europe. Chest 1998, 113:183S-187S.

    PubMed  CAS  Google Scholar 

  17. Niederman MS, Bass JB Jr, Campbell GD, et al.: Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis 1993, 148:1418–1426.

    PubMed  CAS  Google Scholar 

  18. Campbell GD Jr, Silberman R: Drug-resistant Streptococcus pneumoniae. Clin Infect Dis 1998, 26:1188–1195.

    PubMed  Google Scholar 

  19. Breiman RF, Butler JC, Tenover FC, et al.: Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994, 271:1831–1835.

    Article  PubMed  CAS  Google Scholar 

  20. Butler JC, Hofmann J, Cetron MS, et al.: The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention’s Pneumococcal Sentinel Surveillance System. J Infect Dis 1996, 174:986–993.

    PubMed  CAS  Google Scholar 

  21. Doern GV, Brueggemann A, Holley HP Jr, et al.: Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996, 40:1208–1213.

    PubMed  CAS  Google Scholar 

  22. Thornsberry C, Ogilvie P, Kahn J, et al.: Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996–1997 respiratory season. The Laboratory Investigator Group. Diagn Microbiol Infect Dis 1997, 29:249–257.

    Article  PubMed  CAS  Google Scholar 

  23. Pallares R, Linares J, Vadillo M, et al.: Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995, 333:474–480.

    Article  PubMed  CAS  Google Scholar 

  24. Gress TW, Yingling KW, Stanek RJ, et al.: Infection with Streptococcus pneumoniae moderately resistant to penicillin does not alter clinical outcome. Infect Dis Clin Pract 1996, 5:435–439.

    Article  Google Scholar 

  25. Cunha BA, Shea KW: Emergence of antimicrobial resistance in community-acquired pulmonary pathogens. Semin Respir Infect 1998, 13:43–53.

    PubMed  CAS  Google Scholar 

  26. Leggiadro RJ. The clinical impact of resistance in the management of pneumococcal disease. Infect Dis Clin North Am 1997, 11:867–874.

    Article  PubMed  CAS  Google Scholar 

  27. Broome CV, Facklam RR, Fraser DW: Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med 1980, 303:549–552.

    Article  PubMed  CAS  Google Scholar 

  28. Simberkoff MS, Cross AP, Al-Ibrahim M, et al.: Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986, 315:1318–1327.

    Article  PubMed  CAS  Google Scholar 

  29. Fedson DS: Pneumococcal vaccination in the United States and 20 other developed countries, 1981–1996. Clin Infect Dis 1998, 26:1117–1123. A comprehensive status report on the approval and use of pneumococcal vaccine in 21 developed countries, including the United States. Vaccine use is highest in the United States, and its use has increased in the past few years.

    PubMed  CAS  Google Scholar 

  30. Breiman RF: Prevention of pneumococcal disease—a new romance begins. Clin Infect Dis 1998, 26:1124–1126.

    PubMed  CAS  Google Scholar 

  31. Pneumococcal and influenza vaccination levels among adults aged > or = 65 years-United States, 1995. MMWR Morb Mortal Wkly Rep 1997, 46:913–919.

  32. Hak E, van Essen GA, Grobbee DE, et al.: Effectiveness of pneumococcal vaccine. Lancet 1998, 351:1283.

    Article  PubMed  CAS  Google Scholar 

  33. Gold R: Effectiveness of pneumococcal vaccine. Lancet 1998, 351:1283–1284.

    Article  PubMed  CAS  Google Scholar 

  34. Obaro S: Effectiveness of pneumococcal vaccine. Lancet 1998, 351:1284.

    Article  PubMed  CAS  Google Scholar 

  35. Sutton SK: Effectiveness of pneumococcal vaccine. Lancet 1998 351:1284–1285.

    Article  PubMed  CAS  Google Scholar 

  36. Butler JC, Spika JS, Nichol KL, et al.: Effectiveness of pneumococcal vaccine. Lancet 1998, 351:1961.

    Article  PubMed  CAS  Google Scholar 

  37. Steinhoff MC, Moulton L, Clemens J: Effectiveness of pneumococcal vaccine. Lancet 1998, 351:1961–1962.

    Article  PubMed  CAS  Google Scholar 

  38. Ahman H, Kayhty H, Lehtonen H, et al.: Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr Infect Dis J 1998, 17:211–216.

    Article  PubMed  CAS  Google Scholar 

  39. Rennels MB, Edwards KM, Keyserling HL, et al.: Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 1998, 101:604–611.

    Article  PubMed  CAS  Google Scholar 

  40. Dagan R, Melamed R, Zamir O, et al.: Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. Pediatr Infect Dis J 1997, 16:1053–1059.

    Article  PubMed  CAS  Google Scholar 

  41. King JC Jr, Vink PE, Farley JJ, et al.: Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human immunodeficiency virus infection. Pediatrics 1997, 99:575–580.

    Article  PubMed  Google Scholar 

  42. Anderson EL, Kennedy DJ, Geldmacher KM, et al.: Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatr 1996, 128:649–653.

    Article  PubMed  CAS  Google Scholar 

  43. Shann F: Pneumococcal vaccine: time for another controlled trial. Lancet 1998, 351:1600–1601.

    Article  PubMed  CAS  Google Scholar 

  44. Outbreaks of pneumococcal pneumonia among unvaccinated residents of chronic-care facilities—Massachusetts, October 1995, Oklahoma, February 1996, and Maryland, May-June 1996. MMWR Morb Mortal Wkly Rep 1997, 46:60–62.

  45. Nuorti JP, Butler JC, Crutcher JM, et al.: An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. N Engl J Med 1998, 338:1861–1868. Residents of nursing homes and other chronic care facilities are at increased risk for pneumococcal pneumonia, and vaccine needs to be administered to each resident of such facilities. In this nursing home, only 4% of residents had received vaccine. Eleven residents developed lobar pneumonia (attack rate, 13%) due to MRSP serotype 23F, and three bacteremic patients died (case-fatality rate, 27%). Colonization of residents and staff with this pneumococcus and lack of vaccination of the residents contributed to the high attack rate.

    Article  PubMed  CAS  Google Scholar 

  46. Lieberman D, Schlaeffer F, Porath A: Community-acquired pneumonia in old age: a prospective study of 91 patients admitted from home. Age Ageing 1997, 26:69–75.

    Article  PubMed  CAS  Google Scholar 

  47. Marston BJ, Plouffe JF, File TM Jr, et al.: Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997, 157:1709–1718.

    Article  PubMed  CAS  Google Scholar 

  48. Bohte R, Hermans J, vanden Broek PJ: Early recognition of Streptococcus pneumoniae in patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1996, 15:201–205.

    Article  PubMed  CAS  Google Scholar 

  49. Porath A, Schlaeffer F, Pick N, et al.: Pneumococcal community-acquired pneumonia in 148 hospitalized adult patients. Eur J Clin Microbiol Infect Dis 1997, 16:863–870.

    Article  PubMed  CAS  Google Scholar 

  50. Vuori E, Peltola H, Kallio MJ, et al.: Etiology of pneumonia and other common childhood infections requiring hospitalization and parenteral antimicrobial therapy. SE-TU Study Group. Clin Infect Dis 1998, 27:566–572.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Marshall University School of Medicine, 1600 Medical Center Drive, Suite G500, 25701-3655, Huntington, WV, USA

    Maurice A. Mufson MD

Authors
  1. Maurice A. Mufson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mufson, M.A. Pneumococcal pneumonia. Curr Infect Dis Rep 1, 57–64 (1999). https://doi.org/10.1007/s11908-999-0011-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-999-0011-9

Keywords

Search

Navigation